Targeting PERK in cancer therapy presents several challenges:
Selectivity: Ensuring that PERK inhibitors selectively target cancer cells without affecting normal cells is crucial to minimize side effects. Resistance: Cancer cells may develop resistance to PERK inhibitors, necessitating combination therapies or alternative strategies. Toxicity: Given PERK's role in normal cellular stress responses, inhibiting its activity could lead to unintended toxicities.
